EUVIMEDEUVIMED entdecken
Übersichtsarbeit

In vivo Inhibition of Helicobacter pylori through Probiotics and Gastrointestinal Commensals: A Critical Review

Johannes Raphael Westphal, Nadine Koch, Ramiro Vilchez-Vargas, Riccardo Vasapolli, Didem Saka, Peter Malfertheiner, Christian Schulz

Digestive Diseases · 2025

DOI: 10.1159/000546119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive Diseases, 2025. Verfasst von Johannes Raphael Westphal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department II, University Hospital, Ludwig-Maximillians-Universität, Munich, Germany. Hauptthemen laut MEDLINE: Probiotics, Helicobacter pylori, Helicobacter Infections, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Helicobacter pylori eradication is increasingly challenged, due to high antibiotic resistance rates in H. pylori and treatment failure. Consequently, new treatment regimens are needed. Probiotic and gastrointestinal bacteria exert anti-H. pylori activity in vivo, thus being potential add-on candidates for future eradication strategies. Summary: In this review, we summarised the currently available literature for in vivo inhibition of H. pylori. Included studies address anti-H. pylori effects in mouse and rat models caused by potentially beneficial bacteria. Research on literature was further extended to clinical eradication studies in humans. Several bacterial strains, mainly belonging to the Lactobacillus genus, inhibited H. pylori in vivo. In animal studies, probiotic bacteria and commensals reduced H. pylori colonisation and the inflammatory response. Certain probiotic species reduce H. pylori colonisation in humans. Key Messages: Probiotic and gastrointestinal commensals are beneficial in H. pylori eradication therapy. Their current role is the reduction of adverse events and H. pylori load.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsHelicobacter pyloriHelicobacter InfectionsGastrointestinal MicrobiomeGastrointestinal TractHumansAnimalsAnti-Bacterial Agents

Stichwörter der Autor:innen

13 C-Urea Breath TestAnti-Helicobacter pylori effectsBacteriaBifidobacteriumGastrointestinal commensalsHelicobacter pyloriHelicobacter pylori eradicationHelicobacter pylori infectionHelicobacter pylori inhibitionLactobacillusMicrobiotaProbiotic

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Medical Department II, University Hospital, Ludwig-Maximillians-Universität, Munich, Germany.
  • German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • Medical Department Klinik of Gastroenterology, Hepatology and Infectiology, Otto-von-Guericke Universität, Magdeburg, Germany.

Zitieren

APA

Westphal, J. R., Koch, N., Vilchez-Vargas, R., Vasapolli, R., Saka, D., Malfertheiner, P., & Schulz, C. (2025). In vivo Inhibition of Helicobacter pylori through Probiotics and Gastrointestinal Commensals: A Critical Review. Digestive Diseases. https://doi.org/10.1159/000546119

Vancouver

Westphal JR, Koch N, Vilchez-Vargas R, Vasapolli R, Saka D, Malfertheiner P, et al. In vivo Inhibition of Helicobacter pylori through Probiotics and Gastrointestinal Commensals: A Critical Review. Digestive Diseases. 2025. doi:10.1159/000546119

BibTeX
@article{Westphal2025,
  author = {Westphal, Johannes Raphael and Koch, Nadine and Vilchez-Vargas, Ramiro and Vasapolli, Riccardo and Saka, Didem and Malfertheiner, Peter and Schulz, Christian},
  title = {In vivo Inhibition of Helicobacter pylori through Probiotics and Gastrointestinal Commensals: A Critical Review},
  journal = {Digestive Diseases},
  year = {2025},
  doi = {10.1159/000546119}
}
Kostenlos starten →